Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | MARK3 | P27448 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3463523 | 0.81 | ADRA2A (0.33) | ADRA2AADRA2BADRA2CTSHRLMNA | |
| SCHEMBL3086892 | 0.78 | ADRA2A (0.32) | ADRA2AADRA2BADRA2C | |
| SCHEMBL127280 | 0.77 | ALDH1A1 (0.39) | TSHRCYP2D6CYP2C19SMN1; SMN2 | |
| SCHEMBL3132186 | 0.76 | MEN1 (0.35) | ADRA2AADRA2BADRA2CTSHRCYP2D6 | |
| SCHEMBL17710579 | 0.74 | MCHR1 (0.37) | — | |
| SCHEMBL3463971 | 0.74 | HTR7 (0.42) | SMN1; SMN2 | |
| SCHEMBL10492299 | 0.74 | HTT (0.38) | CYP2D6CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL159256 | 0.72 | KDM4E (0.42) | TSHRSMN1; SMN2 | |
| SCHEMBL10757130 | 0.71 | MCHR1 (0.40) | — | |
| SCHEMBL16952206 | 0.71 | ALDH1A1 (0.34) | TSHRCYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240654-A1 | HYDRAZIDE DERIVATIVES | CLARK RICHARD | 2010-09-23 | — | — | US | claimed |
| US-20080132507-A1 | Hydrazide Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-06-05 | — | — | US | claimed |
| EP-1810965-A1 | HYDRAZIDE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2007-07-25 | — | — | EP | claimed |
| US-20100240654-A1 | HYDRAZIDE DERIVATIVES | CLARK RICHARD | 2010-09-23 | — | — | US | disclosed |
| US-20080132507-A1 | Hydrazide Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1810965-A1 | HYDRAZIDE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240654-A1 | HYDRAZIDE DERIVATIVES | H1-10, H1-4, H1-3 | ADRA2A 668/4885ADRA2B 288/4885ADRA2C 690/4885 |
| US-20080132507-A1 | Hydrazide Derivatives | H1-10, H1-4, H1-3 | ADRA2A 668/4885ADRA2B 288/4885ADRA2C 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.